NCT05949099 is a Phase 2 clinical trial of Nirogacestat in Desmoid Tumor, sponsored by Nam Bui.

Who is sponsoring NCT05949099?

NCT05949099 is sponsored by Nam Bui.

What drugs are being tested in NCT05949099?

Interventions in NCT05949099: Nirogacestat, Cryoablation.

What condition does NCT05949099 study?

NCT05949099 studies Desmoid Tumor.

Is NCT05949099 still recruiting?

NCT05949099 is currently recruiting now. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT05949099

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Cryoablation and Nirogacestat for Desmoid Tumor

Recruiting now Phase 2 Last updated 8 September 2025

What this trial tests

Phase 2 trial testing Nirogacestat in Desmoid Tumor in 28 participants. Currently enrolling.

Timeline

15 August 2023

Primary endpoint
1 February 2028

1 February 2028

Quick facts

Lead sponsor	Nam Bui
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	15 August 2023
Primary completion	1 February 2028
Estimated completion	1 February 2028
Sites	1 location across United States

Drugs / interventions tested

Nirogacestat (NIROGACESTAT) — full drug profile →
Cryoablation — full drug profile →

Conditions studied

Desmoid Tumor — all drugs for Desmoid Tumor →

Sponsor

Nam Bui

Who can join

18 and older, any sex, with Desmoid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nirogacestat

Trials testing the same drug.

NCT07259330 — To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants · Phase 1 · active not recruiting
NCT07176689 — Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) · Phase 4 · recruiting
NCT07171619 — Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat · Phase 1 · completed
NCT05879146 — Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study · Phase 2 · recruiting
NCT05573802 — A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethas · Phase 1, PHASE2 · recruiting

Other recruiting trials for Desmoid Tumor

Currently open trials in the same condition.

NCT07176689 — Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) · Phase 4 · recruiting
NCT07170644 — A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) · Phase 2 · active not recruiting
NCT07461246 — Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare) · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05949099 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nam Bui
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05949099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing